S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
NASDAQ:GWPH

GW Pharmaceuticals (GWPH) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$218.96
▼
$218.96
50-Day Range
$216.90
▼
$219.28
52-Week Range
$87.07
▼
$219.57
Volume
N/A
Average Volume
899,771 shs
Market Capitalization
$6.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

GWPH stock logo

About GW Pharmaceuticals (NASDAQ:GWPH) Stock

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Receive GWPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GW Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GWPH Stock News Headlines

March 9, 2023 | powermag.com
China Approves 106 GW of New Coal-Fired Capacity
February 19, 2023 | thestreet.com
Why Nasdaq-Traded Marijuana Stocks Remain Undervalued
June 2, 2023 | Behind the Markets (Ad)
WARNING TO ALL U.S. INVESTORS
May 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>
September 25, 2022 | investing.com
GW Pharmaceuticals PLC (GWPRF)
August 22, 2022 | benzinga.com
Medical Marijuana Market Size Worth $40 Billion by 2028 at 19.2% CAGR, COVID-19 Impact and Global Analysis by The Insight Partners
June 15, 2022 | thestreet.com
Why Pot Stock GW Pharmaceuticals Could Go Even Higher in 2016
March 3, 2022 | msn.com
Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma
February 15, 2022 | marketwatch.com
Medical Marijuana Market Forecast With Trends, Challenges, Growth Drivers, And Top Key Players
June 2, 2023 | Stocks To Trade (Ad)
Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
January 25, 2022 | thestreet.com
These 3 Marijuana-Related Stocks Are Poised for Strong Growth
January 21, 2022 | finance.yahoo.com
GWPH Jan 2023 195.000 put
December 15, 2021 | msn.com
Study Suggests Whole-Plant Medicinal Cannabis Could Be More Effective Than CBD In Epilepsy Treatment
November 1, 2021 | benzinga.com
Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer
October 26, 2021 | finance.yahoo.com
Today's Research Reports on Trending Tickers: Arena Pharmaceuticals Inc. and GW Pharmaceuticals
October 26, 2021 | finance.yahoo.com
GW Pharmaceuticals (GWPH): What Awaits in Q1 Earnings?
August 4, 2021 | law360.com
2 Firms Seek To Lead GW Pharma Suit Over $7.2B Deal
August 4, 2021 | msn.com
Jazz Pharmaceuticals Q2 Revenue Jumps 34% To $751.8M With $109.5M Epidiolex Net Sales, Reaffirms Its 2021 Guidance Of $3.02B
July 15, 2021 | nasdaq.com
GW Pharmaceuticals Plc American Depositary Shares (GWPH)
June 26, 2021 | uk.finance.yahoo.com
GWPH Aug 2021 165.000 call
June 26, 2021 | uk.finance.yahoo.com
GWPH Aug 2021 95.000 call
June 26, 2021 | uk.finance.yahoo.com
GWPH Aug 2021 85.000 put
June 21, 2021 | uk.finance.yahoo.com
GWPH Jan 2022 60.000 put
June 21, 2021 | uk.finance.yahoo.com
GWPH Jan 2022 80.000 call
June 21, 2021 | uk.finance.yahoo.com
GWPH Jan 2022 140.000 put
June 8, 2021 | ca.finance.yahoo.com
GWPH Jan 2022 125.000 put
May 15, 2021 | uk.finance.yahoo.com
GW Pharmaceuticals PLC Stock Is Believed To Be Significantly Undervalued
May 6, 2021 | prnewswire.com
CBD Oil Extract Market Share Projected To Reach $25.57 Billion by 2027
See More Headlines


GWPH Company Calendar

Last Earnings
11/03/2020
Today
6/02/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GWPH
CUSIP
N/A
CIK
1351288
Web
www.gwpharm.com
Phone
44-12-2326-6800
Fax
N/A
Employees
1,161
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-9,020,000.00
Net Margins
-11.05%
Pretax Margin
N/A
Return on Equity
-7.46%
Return on Assets
-6.13%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
5.13
Quick Ratio
4.31

Sales & Book Value

Annual Sales
$311.33 million
Price / Sales
22.05
Cash Flow
$0.01 per share
Price / Cash Flow
18,588.22
Book Value
$23.48 per share
Price / Book
9.33

Miscellaneous

Outstanding Shares
31,349,000
Free Float
N/A
Market Cap
$6.86 billion
Optionable
Optionable
Beta
2.15

Key Executives

  • Mr. Justin D. GoverMr. Justin D. Gover (Age 50)
    CEO & Exec. Director
    Comp: $1.19M
  • Mr. Scott M. Giacobello (Age 51)
    Chief Financial Officer
    Comp: $743.33k
  • Mr. Douglas B. Snyder (Age 57)
    Chief Legal Officer & Sec.
    Comp: $787.02k
  • Dr. Volker Knappertz M.D. (Age 56)
    D.Sc., Chief Medical Officer
    Comp: $830.47k
  • Mr. Christopher John ToveyMr. Christopher John Tovey (Age 56)
    Chief Operating Officer
  • Kristen Cardillo
    VP of Corp. Communication
  • Ms. Tina St. Leger
    Chief HR Officer
  • Prof. Ben Whalley
    Head of Discovery Research
  • Mr. Darren S. Cline (Age 57)
    U.S. Chief Commercial Officer

Key Competitors

View All Competitors













GWPH Stock - Frequently Asked Questions

How were GW Pharmaceuticals' earnings last quarter?

GW Pharmaceuticals plc (NASDAQ:GWPH) released its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.27. The biopharmaceutical company earned $137.10 million during the quarter, compared to analyst estimates of $97.66 million. GW Pharmaceuticals had a negative net margin of 11.05% and a negative trailing twelve-month return on equity of 7.46%. The company's revenue was up 50.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.04) EPS.

What is Justin Gover's approval rating as GW Pharmaceuticals' CEO?

14 employees have rated GW Pharmaceuticals Chief Executive Officer Justin Gover on Glassdoor.com. Justin Gover has an approval rating of 80% among the company's employees.

What other stocks do shareholders of GW Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Intel (INTC), Netflix (NFLX), Gilead Sciences (GILD), Aurora Cannabis (ACB) and Advanced Micro Devices (AMD).

What is GW Pharmaceuticals' stock symbol?

GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."

What is GW Pharmaceuticals' stock price today?

One share of GWPH stock can currently be purchased for approximately $218.96.

How much money does GW Pharmaceuticals make?

GW Pharmaceuticals (NASDAQ:GWPH) has a market capitalization of $6.86 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does GW Pharmaceuticals have?

The company employs 1,161 workers across the globe.

How can I contact GW Pharmaceuticals?

GW Pharmaceuticals' mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The official website for the company is www.gwpharm.com. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at sschultz@gwpharm.com.

This page (NASDAQ:GWPH) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -